...
首页> 外文期刊>Circulation journal >Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-.
【24h】

Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-.

机译:日本房颤患者使用华法林的决定因素和国际标准化比率水平。 -J-RHYTHM注册中心的子分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Determinants of warfarin use and anticoagulation levels in atrial fibrillation (AF) patients have not been clarified thoroughly. METHODS AND RESULTS: A total of 6,324 patients with non-valvular AF and congestive heart failure, hypertension, age, diabetes, prior stroke (CHADS) score >/= 1 were used to investigate determinants of warfarin use, and 6,932 patients with AF receiving warfarin were used to investigate determinants of international normalized ratio (INR) of prothrombin time. Target INR levels for non-valvular AF patients were 1.6-2.6 for patients aged >/= 70 years and 2-3 for patients aged < 70 years. Those for patients with valvular AF were 2-3. Patients with non-valvular AF and CHADS score >/= 1 receiving warfarin (n = 5,614) more frequently had permanent AF, congestive heart failure, and stroke or transient ischemic attack (TIA), and had higher CHADS scores than those not receiving warfarin. Determinants of warfarin use were age (>/= 60 years), AF type (persistent and permanent), and comorbidities (congestive heart failure, diabetes mellitus, and prior stroke or TIA). Use of antiplatelet drugs was a negative determinant of warfarin use. Only 53% of patients met the target INR levels. Determinants for the meeting of the target INR level (vs. lower INR level) were age (>/= 60 years), permanent AF, hypertension, and prior stroke or TIA. Use of antiplatelet drugs was a negative determinant of the INR level. CONCLUSIONS: Currently in Japan, adherence to the guidelines regarding anticoagulation therapy is limited (UMIN Clinical Trials Registry UMIN000001569).
机译:背景:心房颤动(AF)患者中使用华法林的决定因素和抗凝水平尚未完全阐明。方法和结果:总共6,324例非瓣膜性房颤并发充血性心力衰竭,高血压,年龄,糖尿病,先前卒中(CHADS)得分> / = 1的患者被调查用于研究华法林的决定因素,而6,932例房颤患者接受了华法林用于研究凝血酶原时间的国际归一化比率(INR)的决定因素。对于> / = 70岁的患者,非瓣膜性AF患者的目标INR水平为1.6-2.6,对于<70岁的患者,其目标INR水平为2-3。瓣膜性AF的患者为2-3例。非瓣膜性房颤且CHADS评分> / = 1的患者接受华法林治疗(n = 5,614)的频率更高,永久性AF,充血性心力衰竭和中风或短暂性脑缺血发作(TIA),并且CHADS得分高于未接受华法林的患者。使用华法林的决定因素是年龄(> / = 60岁),房颤类型(持续的和永久的)和合并症(充血性心力衰竭,糖尿病和先前的中风或TIA)。抗血小板药物的使用是华法林使用的负面决定因素。只有53%的患者达到了目标INR水平。达到目标INR水平(相对较低的INR水平)的决定因素是年龄(> / = 60岁),永久性AF,高血压和先前卒中或TIA。抗血小板药物的使用是INR水平的负决定因素。结论:目前在日本,抗凝治疗指南的遵守受到限制(UMIN临床试验注册处UMIN000001569)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号